By integrating digitization and machine learning, there is an opportunity to deliver personalized care to all patients and scale precision dosing with minimal physician involvement, maximizing the effectiveness and accessibility of these drugs.
Some patients reach a point where ongoing TKI therapy can cause more harm than good. New data can simplify the decision to discontinue treatment.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Abbvie’s Viekira Pak Costs $6.5 Million a Year in Avoidable Costs, Puts Patients at Greater Risk// // In January 2015, Advera Health released a Drug Safety Monitor analysis comparing the safety of then newly approved Hepatitis C drugs Viekira Pak to Harvoni and Solvaldi (hereafter just Harvoni). Our analysts concluded, …both Harvoni and Sovaldi appear […]
In the past several months the “war on drugs” has intensified. But the war is no longer defined as an offensive against illegal narcotics, but one against pharmaceutical companies and the increasing costs of specialty drugs. With the donkeys, elephants, and other political animals gearing up for the 2016 electoral stampede, it seems that each […]
We all know that most medical treatments have potential side effects, some more than others of course. But it can be difficult to break down and conceptualize the numbers as far as determining if certain therapies will do more harm than good. That’s where Number Needed to Treat, or N.N.T. and Number Needed to Harm N.N.H. […]